Recent

% | $
Quotes you view appear here for quick access.

Metabolix, Inc. Message Board

akanz2 82 posts  |  Last Activity: Jul 6, 2016 8:23 PM Member since: Feb 12, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Probable bottom here and now!

    by learnigisdkey Mar 11, 2016 10:59 AM
    akanz2 akanz2 Mar 11, 2016 3:05 PM Flag

    Mehro Your post is an example of why Yahoo message board is largely a waste of time .
    You will find a history of my posts on ZSPH and RLYP going back well over a year.
    The HyperKalemia market is a large market . Its unlikely 1 company will take it all.

    In the CKD space there are issues with speed of action and drug /drug interactions that favor ZS-9 ...however these are less of a concern in the CHF market as these patients are usually on fewer drugs.
    Bottom line ...Veltassa is being prescribed and has the opportunity to establish a market share before ZS-9 is approved .
    At these levels RLYP is worth buying as a spec buy .
    JMO
    AK

  • Reply to

    Probable bottom here and now!

    by learnigisdkey Mar 11, 2016 10:59 AM
    akanz2 akanz2 Mar 11, 2016 1:49 PM Flag

    Actually Learning I agree with U ....and have started a small long position..
    My wife works in dialysis and runs a stage 4 CKD clinic and her dept has started to prescribe Veltassa.
    RLYP has a major cash burn problem but once major hospitals ( such as where my wife works ) start prescribing and insurance starts covering ( I believe Veltassa is now on Medicare formulary ) sales will pick up..

    As a note ...I owned ZSPH and still believe that ZS-9 will dominate the CKD market but Veltassa will find some market share , especially in the CHF market .
    Good luck
    AK

MBLX
0.4151-0.0449(-9.76%)Aug 24 3:59 PMEDT